IFBC prepared a financial opinion for Colosseum Dental Group AG on the financial adequacy of the value of a subsidiary.
The Colosseum Dental Group is a leading pan-European dentistry group. The main owner of Colosseum Dental is Jacobs Holding AG.
In late March 2021, the Swiss affiliate of the global pharmaceutical company Takeda successfully divested part of its home delivery business to a Swiss partner who will provide these services on behalf of Takeda in the future. The divestment also included an existing Pharmacy serving part of a German-speaking region of Switzerland.
IFBC acted as exclusive M&A advisor to Takeda during the entire transaction process. IFBC supported Takeda in preparing and structuring the transaction, conducted a meaningful buyer approach, coordinated the due diligence, and supported the contract negotiations.
Takeda is a global, R&D-driven biopharmaceutical leader headquartered in Japan. Takeda focuses on four therapeutic areas: oncology, rare genetic and hematology, neuroscience, and gastroenterology. Over 50’000 Takeda employees are committed to improving quality of life for patients and to working with partners in health care in more than 70 countries.
IFBC supported the restructuring of Unisto’s name badges producing and distributing business unit. Various strategic alternatives for the business unit were assessed and their implementation was subsequently supported. As a result, Unisto will focus on its core activities in the future.
Unisto is a leading company in the fields of brand profiling, security seals and digital security solutions. Founded in 1926, Unisto, based in Horn (Canton Thurgau), today employs over 600 people worldwide.
IFBC was engaged by Sonova to assess the underlying cost of capital rates as well as the applied model for the valuation of the subsidiaries in the context of STAF in terms of best practice and to confirm the correct implementation. As part of the review, the planning assumptions made had to be checked for plausibility from an external perspective.
The Sonova Group is the world’s leading provider of hearing instruments. The company is listed on the SIX Swiss Exchange.
IFBC valued selected intangible assets for SingularDTV. The valuation led to an increase in SingularDTV management’s financial visibility for the upcoming further development of the company.
SingularDTV is a pioneer in the decentralised entertainment industry and in raising funds through an initial coin offering.
IFBC was engaged by the board of directors of Aryzta AG to prepare a Fairness Opinion assessing the public tender offer of an investor. As a qualified evaluator pursuant to Article 30(6) Takeover Ordinance, IFBC is suitably qualified to prepare Fairness Opinions.
Aryzta is a global company and market leader specialized in bakery products.
As an expert, IFBC quantified the financial damages in connection with a large, international M&A transaction in the context of arbitration proceedings. The IFBC team prepared two expert reports and, in addition, Dr. Thomas Vettiger testified as an expert witness before the arbitral tribunal in Zurich as part of these arbitration proceedings under the rules of International Arbitration of the SCAI. The process was settled with an amicable agreement between the parties.
IFBC valued for Siegfried Holding AG as issuer two privately placed hybrid convertible bonds in the total amount of CHF 80 million.
The Siegfried Group is a global life sciences company and currently employs about 3500 people at eleven sites on three continents. Siegfried is active in manufacturing pharmaceutical APIs (and their intermediates) as well as drug products for the pharmaceutical industry and provides development services.
On 29 January 2021, OFFIX Holding AG (which belongs to the Swiss PEG Papeteristen Einkaufsgenossenschaft) and the Swiss Office World Holding AG (which belongs to the international MTH Retail Group Holding GmbH), announced that they intend to bundle their Swiss business in the new Office World Group AG.
IFBC acted as Financial Advisor to OFFIX Holding AG for this important transaction. IFBC particularly supported its client with valuation and transaction price considerations and in price negotiations.
Today OFFIX Holding AG is one of the leading players in the area of paper and stationery products in Switzerland. It has an annual turnover of around CHF 240mn and a total headcount of 235 employees.
IFBC supported Energie Ausserschwyz AG as exclusive financial advisor and guided the company through the entire financing process. The company signed a loan agreement (amount CHFm 60) with a Swiss bank and raised additional equity from a strategic partner.
With the realisation of the district heating project, which involves the construction of a wood-fired combined heat and power plant, a biogas plant and a district heating network, Energie Ausserschwyz AG will in the future supply the population of the Canton of Schwyz with environmentally friendly heat and electricity. Energie Ausserschwyz AG is thus making a significant contribution to the switch to more ecologically energy sources.
On 27 January 2020, the leading Swiss digital agency Hinderling Volkart AG (“Hinderling Volkart”) announced that it will become part of the Dutch company Dept Holding B.V. (“Dept”). Hinderling Volkart from Zurich as well as the two subsidiaries Hinderling Volkart Bern and HV Italic from Basel are joining the internationally expanding Dept.
IFBC acted as exclusive M&A advisor to Hinderling Volkart during the entire transaction. Among others, IFBC performed a structured international buyer approach, developed the transaction structure, organized the due diligence and led the negotiations.
Hinderling Volkart is a multiple award-winning Swiss digital agency. Its approximately 60 employees work at three locations in Zurich, Bern and Basel for clients such as SwissRe, Edelweiss, Swiss and Switzerland Tourism.
IFBC has been mandated by Octapharma to prepare a valuation in the context of STAF to the attention of the Swiss tax authorities. The valuation of Octapharma has been based on the DCF approach and considers tax-specific circumstances. The resulting value was benchmarked using multiples of comparable companies and transactions.
Octapharma Group is specialized in the development and production of preparations from human plasma. The group focuses on highly pure, virus-inactivated drugs for the treatment of diseases in the fields of hematology, immunology and intensive care medicine.